100% Virtual Meeting
Saturday, April 17th | 09h30 – 11h30

 

Virtual Meeting - Moving forward in Fabry Disease Cardiopathy | AMICUS
Important security information:
Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation1.
Treatment with GALAFOLD must be initiated and supervised by specialist physicians with experience in the diagnosis and treatment of Fabry disease.
This medicine is subject to additional monitoring, which will speed up the detection of new information about your safety.
Healthcare professionals are invited to report suspected adverse reactions.
Bibliography:
1.Galafold summary of products characteristics®. May 2020
Galafold, INN-migalastat hydrochloride (europa.eu)
P-ESPO-GA-21-001
 
Comentários recentes
    Latest Events
    Ads
    Event Search
    Latest Posts